270 related articles for article (PubMed ID: 31961478)
1. Short-Term Efficacy of Different First-Line Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Zhang BB; Zhu W; Tao J; Li Y; Du CC; Chen YX; Liu YD
Clin Transl Sci; 2020 May; 13(3):589-598. PubMed ID: 31961478
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Zheng Q; Min S; Zhou Y
BMC Cancer; 2022 Jun; 22(1):674. PubMed ID: 35725420
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Zhang SH; Liu GF; Li XF; Liu L; Yu SN
J Cell Physiol; 2018 Apr; 233(4):3352-3374. PubMed ID: 28926090
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis.
Lv Y; Cao Z; Pan J; Gong E; Zheng H; Cai X
Open Med (Wars); 2021; 16(1):183-191. PubMed ID: 33585694
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
Liu GF; Li GJ; Zhao H
J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.
Natale RB
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):27-31. PubMed ID: 15339056
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis.
Liu T; He Z; Dang J; Li G
Radiat Oncol; 2019 Mar; 14(1):55. PubMed ID: 30925881
[TBL] [Abstract][Full Text] [Related]
11. A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer.
Jiang XP; Rui XH; Guo CX; Huang YQ; Li Q; Xu Y
Oncotarget; 2017 Mar; 8(12):19125-19136. PubMed ID: 27835912
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
Wang C; Song DJ; Xu ZL; Xie SP; Hu JH
Exp Mol Med; 2017 Sep; 49(9):e383. PubMed ID: 28960212
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy analysis of third-generation plus platinum doublets in the first-line chemotherapy of advanced non-small cell lung cancer].
Zhao LD; Zhang XR; Li JL; Wang ZP; Wang Y; Hao XZ; Hu XS; Zhou SY; Sun Y; Shi YK
Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(22):1527-31. PubMed ID: 22944054
[TBL] [Abstract][Full Text] [Related]
15. Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Wang Y; Xu L; Meng X; Qin Z; Wang Y; Chen C; Wang Y; Zhou X; Zhang Q; Xia J; Song N
Cell Physiol Biochem; 2018; 50(1):1-14. PubMed ID: 30293075
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Li C; Sun Y; Pan Y; Wang Q; Yang S; Chen H
Lung; 2010 Oct; 188(5):359-64. PubMed ID: 20703493
[TBL] [Abstract][Full Text] [Related]
17. A systematic overview of chemotherapy effects in non-small cell lung cancer.
Sörenson S; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
[TBL] [Abstract][Full Text] [Related]
18. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
19. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
20. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Chang Q; Zhang Y; Xu J; Zhong R; Qiang H; Zhang B; Han B; Qian J; Chu T
Thorac Cancer; 2019 May; 10(5):1043-1050. PubMed ID: 30900826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
